Bod Australia achieved record medicinal cannabis sales growth during FY21, dispensing 12,187 products, a 212% increase on the previous year.
The company recorded 17% quarter-on-quarter growth during Q4 FY21, with 4,441 units sold, compared to 3,805 in Q3. It has now sold 16,267 medicinal cannabis product units since fulfilling its first prescriptions in 2019.
Bod said it retained 46% market share in Australia for full plant, high-CBD products in FY21, with 65% of prescriptions being repeats.
The growth in prescription volumes was supported by ongoing educational initiatives with healthcare professionals, as well as Bod’s nationwide clinical study investigating the efficacy of its products in treating anxiety, insomnia and post-traumatic stress disorder.
CEO Jo Patterson said: “During FY21, the company maintained nearly a 50% market share for the total addressable market for high-CBD products in Australia. While repeat prescriptions remained at a high level, Bod also increased its patient and doctor acquisitions through ongoing educational initiatives and its relationships with approved prescribers.
“We anticipate increased demand for our medicinal cannabis product suite over the coming quarter and beyond. A number of new products are currently being introduced and operations in the UK continue to scale pleasingly.”